Targeting Cancer at the Protein-Membrane Interface

在蛋白质-膜界面靶向癌症

• 批准号: 10580562
• 负责人: Johannes Morstein
• 金额: $ 16.31万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10580562
• 关键词: Address; Area; Binding; Biological; Biological Products; Cancer Biology; Cell Membrane Permeability; Cell membrane; Cells; Chemical Structure; Chemistry; Complement; Conceptions; Data; Development; Diffusion; Disease; Drug Design; Drug Targeting; Electrostatics; Endocytosis; Enzymes; Event; FRAP1 gene; G-Protein-Coupled Receptors; Goals; Growth; Guanosine Triphosphate Phosphohydrolases; Human; Interdisciplinary Study; Ion Channel; KRAS2 gene; Lateral; Libraries; Link; Lipids; Liposomal Doxorubicin; MAP Kinase Gene; Malignant Neoplasms; Membrane; Membrane Proteins; Mentors; Mentorship; Methods; Natural Products; Nature; PIK3CG gene; Pathway interactions; Permeability; Pharmaceutical Preparations; Pharmacology; Phosphotransferases; Process; Property; Proteins; RNA vaccine; Research; Role; Signal Pathway; Signal Transduction; Site; Structure-Activity Relationship; Testing; Training; WNT Signaling Pathway; anticancer research; biophysical properties; cancer immunotherapy; cancer pharmacology; cancer therapy; career; combinatorial; combinatorial chemistry; convict; design; drug discovery; experience; high throughput screening; holistic approach; inhibitor; innovation; insight; lipophilicity; nanotherapy; new therapeutic target; novel; novel strategies; pharmacologic; pharmacophore; receptor; recruit; screening; skills; small molecule; uptake

Project Summary Significant progress in human cancer therapy in the last decade has been driven by conceptionally new approaches to treating cancer, including cancer immunotherapy, cancer nanotherapy (e.g. liposomal doxorubicin or mRNA vaccines), or new types of biologics and small molecules. I propose to develop new approaches to targeting protein-membrane interactions that could yield unprecedented methods to modulate cancer signaling and generate useful paradigms for pharmacology at large. The role of protein-membrane and drug-membrane interactions will be explored and targeted on various levels, each highly relevant to cancer pharmacology: 1. Cancer signaling, a hallmark of cancer, is largely dependent on the recruitment of kinases (e.g. PI3K or PKC) and GTPases (e.g. RAS) to hotspots localized at the inner plasma membrane leaflet. I aim to develop bifunctional inhibitors with the capacity to modulate these interactions as a new approach to target cancer signaling. 2a. Membrane-integrated receptors are also key players in cellular signaling (e.g. enzyme-linked receptors or GPCRs). Recently, a number of pharmacophores have been discovered that target these proteins directly from the intramembrane space. These `Intramembrane pharmacophores' first partition into the membrane and then engage their target through lateral diffusion and entry. I aim to systematically modulate membrane exposed pharmacophore sites to explore principles governing the action of these pharmacophores which in turn will aid in the discoveries of new intramembrane pharmacophores. 2b. The majority of bioactive molecules acts on membrane proteins or intracellular targets and therefore needs to partition into or cross biological membranes. I propose to use combinatorial chemistry to discover new principles and chemical structures that modulate and privilege pharmacophores for cellular uptake. These will be tested in live cells using high throughput assays as a holistic approach to covering all possible uptake mechanisms on the first level of screening (e.g. endocytosis, transporters, passive diffusion). Combined, the proposed research will provide important insights into the functional role of protein- membrane interactions in cancer signaling and their vulnerability to small molecule-based modulation. Each of the proposed directions has the potential to yield fundamentally new and unprecedented approaches to targeting cancer and other diseases. My mentor and collaborators have extensive experience in cancer pharmacology, drug discovery, and the biophysical characterization of protein-membrane interfaces and will provide the training needed to conduct the proposed research. They will also provide the mentorship needed to acquire all skills and preliminary data needed for a successful transition to an independent career in cancer research.

项目摘要 在过去十年中，人类癌症治疗的重大进展是由概念上的新驱动的 治疗癌症的方法，包括癌症免疫疗法，癌症纳米疗法（例如脂质体阿霉素 或mRNA疫苗），或新型的生物制剂和小分子。我建议开发新的方法 靶向可能产生前所未有的方法调节癌症信号的蛋白质膜相互作用 并为整个药理学生成有用的范例。蛋白质膜和药物膜的作用 相互作用将被探索和针对各种水平，每个级别都与癌症药理学高度相关： 1。癌症信号是癌症的标志，在很大程度上取决于激酶的募集（例如PI3K或PKC） 和GTPases（例如RAS）到位于内部质膜叶片的热点。我的目标是发展双功能 具有调节这些相互作用作为靶向癌症信号的新方法的抑制剂。 2a。膜积分受体也是细胞信号传导的关键参与者（例如，酶联受体或 GPCR）。最近，已经发现了许多药理直接靶向这些蛋白 膜内空间。这些“膜内药剂团”的第一个分区到膜中，然后 通过横向扩散和进入进行目标。我的目标是系统地调节暴露的膜 探索有关这些药理作用的原理的药效站点，这些原理又将有助于 在新的膜内药算术的发现中。 2b。大多数生物活性分子作用于膜蛋白或细胞内靶标，因此需要 分割成或跨生物膜。我建议使用组合化学发现新的 调节和特权的药理以用于细胞摄取的原理和化学结构。这些会 使用高吞吐量测定在活细胞中测试，作为覆盖所有可能吸收的整体方法 筛查第一级的机制（例如内吞作用，转运蛋白，被动扩散）。 拟议的研究结合在一起，将为蛋白质的功能作用提供重要的见解。 癌症信号传导中的膜相互作用及其对基于小分子的调制的脆弱性。 每个提议的方向都有可能产生新的新事物和前所未有的 靶向癌症和其他疾病的方法。 我的导师和合作者在癌症药理学，药物发现和 蛋白质膜界面的生物物理表征，将提供进行所需的训练 拟议的研究。他们还将提供获得所有技能和初步数据所需的指导 成功过渡到癌症研究独立职业所需。